Aegis set a $12.00 price target on Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) in a research note released on Monday. The brokerage currently has a a buy rating on the biopharmaceutical company’s stock.
Shares of Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) opened at 6.98 on Monday. The stock’s market cap is $305.36 million. Corbus Pharmaceuticals Holdings has a one year low of $1.01 and a one year high of $7.88. The company has a 50-day moving average of $4.55 and a 200 day moving average of $3.04.
Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last announced its quarterly earnings results on Monday, August 15th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by $0.03. Corbus Pharmaceuticals Holdings had a negative net margin of 890.44% and a negative return on equity of 107.10%. On average, equities analysts forecast that Corbus Pharmaceuticals Holdings will post ($0.40) earnings per share for the current fiscal year.
In other news, insider Barbara White acquired 38,000 shares of the firm’s stock in a transaction dated Wednesday, August 17th. The stock was acquired at an average cost of $3.15 per share, with a total value of $119,700.00. Following the completion of the acquisition, the insider now owns 161,067 shares of the company’s stock, valued at $507,361.05. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Sean F. Moran acquired 148,960 shares of the firm’s stock in a transaction dated Thursday, August 18th. The stock was purchased at an average cost of $3.32 per share, with a total value of $494,547.20. Following the completion of the acquisition, the chief financial officer now directly owns 216,410 shares of the company’s stock, valued at approximately $718,481.20. The disclosure for this purchase can be found here. 11.60% of the stock is currently owned by company insiders.
About Corbus Pharmaceuticals Holdings
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases.
Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.